Tuesday, November 13, 2012
Infinity Pharmaceuticals Inc., of Cambridge, Mass., released new data from its completed Phase I study of IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.